Page 2,280«..1020..2,2792,2802,2812,282..2,2902,300..»

Scientists come closer to ‘mending broken hearts’ by using gene therapy to repair muscles damaged in heart attacks

Posted: August 22, 2013 at 4:42 pm

Scientists have come a step closer to being able to repair the damage done by heart attacks, using a cocktail of genes to transform scar tissue into working heart muscles.

Novel techniques to mend broken hearts using gene therapy and stem cells represent a major new frontier in the treatment of heart disease.

In the latest breakthrough, achieved by researchers at the Gladstone Institute of Cardiovascular Disease in California, researchers were able to re-programme scar-forming cells into heart muscle cells, some of which were capable of transmitting the kind of electrical signals that make the heart beat, according to the latest issue of the Stem Cell Reports journal.

The same team demonstrated their technique last year in live mice, transforming scar-forming cells, called fibroblasts, into beating heart muscle cells, but this is the first time that human fibroblasts have been re-programmed in this way.

So far, the work with human fibroblasts has only been done in the lab, but it paves the way for new treatments for heart attack victims. Researchers said that the cocktail of genes used to regenerate cells could one day be replaced with small drug-like molecules that would offer safer and easier delivery.

We've now laid a solid foundation for developing a way to reverse the damage [done by a heart attack] something previously thought impossible and changing the way that doctors may treat heart attacks in the future, said Dr Deepak Srivastava, director of cardiovascular disease at the Gladstone Institutes. Our findings here serve as a proof of concept that human fibroblasts can be re-programmed successfully into beating heart cells.

In 2012, Dr Srivastava and his team reported in the journal Nature that, by injecting three genes into the hearts of live mice that had been damaged by heart attack, fibroblasts could be turned into working heart cells.

The scientists attempted the same technique using human fibroblasts from foetal heart cells, embryonic stem cells and neonatal skin cells, injected with genes in petri dishes in the lab. An increased number of genes was required to transform the human cells, and the efficiency of the transformed cells was low, but the team were encouraged by the results.

While almost all the cells in our study exhibited at least a partial transformation, about 20 per cent of them were capable of transmitting electrical signals a key feature of beating hearts, said Gladstone staff scientist Ji-dong Fu, the studys lead author.

The number of people who survive heart attacks has increased considerably in recent decades. The British Heart Foundation (BHF) said earlier this year that 70 per cent of women and 68 per cent of men were now surviving. However, success in keeping people alive after a heart attack has led to a rise in the number of people suffering from the long-term after-effects, which include debilitating heart failure.

More:
Scientists come closer to 'mending broken hearts' by using gene therapy to repair muscles damaged in heart attacks

Posted in Gene therapy | Comments Off on Scientists come closer to ‘mending broken hearts’ by using gene therapy to repair muscles damaged in heart attacks

John Chick: Giving diabetes the boot

Posted: August 22, 2013 at 4:42 pm

CFL player John Chick sets up 9-year-old Jack, a football fan with type 1 diabetes, for field goal victory. The

TORONTO , Aug. 22, 2013 /CNW/ - CFL player John Chick sets up 9-year-old Jack, a football fan with type 1 diabetes, for field goal victory. The defensive end, who also lives with the disease and wears an insulin pump on the field, is helping to Kick Diabetes with Sun Life Financial to raise awareness for diabetes research and management.

Image with caption: "CFL player John Chick sets up 9-year-old Jack, a football fan with type 1 diabetes, for field goal victory. The defensive end, who also lives with the disease and wears an insulin pump on the field, is helping to Kick Diabetes with Sun Life Financial to raise awareness for diabetes research and management. (CNW Group/Sun Life Financial Inc.)". Image available at: http://photos.newswire.ca/images/download/20130822_C7499_PHOTO_EN_30041.jpg

SOURCE: Sun Life Financial Inc.

View original post here:
John Chick: Giving diabetes the boot

Posted in Diabetes | Comments Off on John Chick: Giving diabetes the boot

Stem cell therapy treats animal ailments, vets see improvement – Video

Posted: August 22, 2013 at 4:41 pm


Stem cell therapy treats animal ailments, vets see improvement
Stem cell therapy is typically tied to controversy but now, some Southern Arizona veterinarians are turning to a different form of the cutting edge treatment...

By: kgun9

Go here to see the original:
Stem cell therapy treats animal ailments, vets see improvement - Video

Posted in Cell Therapy | Comments Off on Stem cell therapy treats animal ailments, vets see improvement – Video

Understanding the basics of stem cell therapy (First Part)

Posted: August 22, 2013 at 4:41 pm

HUMAN nature has it that when there is something new, be it related to food, enhancements to ones appearance, and even in ones search for answers and treatments to an illness, one may be most willing to brave and enter that unknown territory.

I had the privilege of meeting a very remarkable woman, diagnosed with the Big C of the liver, who, in her desire to prolong her days, agreed to go through stem cell therapy.

In the course of our conversation, I realized that, patients must be given the correct information, and should be armed with the necessary knowledge of the treatment modalities, including success and failure rates, complications, cost and expectations.

This applies not only to what is new, but, even in the most tested of treatment options, patients have the right to know and understand.

Stem cell therapy is one breakthrough in Medical Science. It shows a lot of promise and potential in treating diseases. Stem cell therapy is an intervention strategy where new adult stem cells are introduced into damaged or diseased tissues, in order to treat the disease or injury.

These cells are present during the early stages of life and have the remarkable potential to develop into many different types of cells, and in many tissues, they serve as an internal repair system: they divide to replace and replenish cells that have been diseased.

Research directed to the benefits and usefulness of stem cells, when introduced to a given person with a given injury or illness like the Big C, Diabetes, baldness, leukemia, to name a few, has given rise to clinics and centers offering such services. There are just a few facts that I would like to touch before we get too excited to try it out:

Our body use different types of tissue-specific stem cells to fit a particular purpose. The bone marrow for example has the capacity to regenerate the blood cells.

Stem cells directed to the brain or the pancreas or liver or any organ for that matter must be specific to that organ in order for it to become effective. It is very unlikely then to think that one needs JUST A SINGLE CELL TYPE to treat a multitude of unrelated diseases that involve different tissues or organs.

Once we understand this basic principle of how the stem cells work in the body, we are freed from the incorrect idea that stem cell therapy is a CURE ALL treatment modality.

Read the original here:
Understanding the basics of stem cell therapy (First Part)

Posted in Cell Therapy | Comments Off on Understanding the basics of stem cell therapy (First Part)

Stem cells: Egg engineers

Posted: August 21, 2013 at 10:49 am

ILLUSTRATION BY VIKTOR KOEN

Since last October, molecular biologist Katsuhiko Hayashi has received around a dozen e-mails from couples, most of them middle-aged, who are desperate for one thing: a baby. One menopausal woman from England offered to come to his laboratory at Kyoto University in Japan in the hope that he could help her to conceive a child. That is my only wish, she wrote.

The requests started trickling in after Hayashi published the results of an experiment that he had assumed would be of interest mostly to developmental biologists1. Starting with the skin cells of mice in vitro, he created primordial germ cells (PGCs), which can develop into both sperm and eggs. To prove that these laboratory-grown versions were truly similar to naturally occurring PGCs, he used them to create eggs, then used those eggs to create live mice. He calls the live births a mere 'side effect' of the research, but that bench experiment became much more, because it raised the prospect of creating fertilizable eggs from the skin cells of infertile women. And it also suggested that men's skin cells could be used to create eggs, and that sperm could be generated from women's cells. (Indeed, after the research was published, the editor of a gay and lesbian magazine e-mailed Hayashi for more information.)

Ewen Callaway reports on the ethical challenges of using lab-made sperm and egg cells in fertility treatments.

You may need a more recent browser or to install the latest version of the Adobe Flash Plugin.

Despite the innovative nature of the research, the public attention surprised Hayashi and his senior professor, Mitinori Saitou. They have spent more than a decade piecing together the subtle details of mammalian gamete production and then recreating that process in vitro all for the sake of science, not medicine. Their method now allows researchers to create unlimited PGCs, which were previously difficult to obtain, and this regular supply of treasured cells has helped to drive the study of mammalian reproduction. But as they push forward with the scientifically challenging transition from mice to monkeys and humans, they are setting the course for the future of infertility treatments and perhaps even bolder experiments in reproduction. Scientists and the public are just starting to grapple with the associated ethical issues.

It goes without saying that [they] really transformed the field in the mouse, says Amander Clark, a fertility expert at the University of California, Los Angeles. Now, to avoid derailing the technology before it's had a chance to demonstrate its usefulness, we have to have conversations about the ethics of making gametes this way.

In the mouse, germ cells emerge just after the first week of embryonic development, as a group of around 40 PGCs2. This little cluster goes on to form the tens of thousands of eggs that female mice have at birth, and the millions of sperm cells that males produce every day, and it will pass on the mouse's entire genetic heritage. Saitou wanted to understand what signals direct these cells throughout their development.

Over the past decade, he has laboriously identified several genes including Stella, Blimp1 and Prdm14 that, when expressed in certain combinations and at certain times, play a crucial part in PGC development3, 4, 5. Using these genes as markers, he was able to select PGCs from among other cells and study what happens to them. In 2009, from experiments at the RIKEN Center for Developmental Biology in Kobe, Japan, he found that when culture conditions are right, adding a single ingredient bone morphogenetic protein 4 (Bmp4) with precise timing is enough to convert embryonic cells to PGCs2. To test this principle, he added high concentrations of Bmp4 to embryonic cells. Almost all of them turned into PGCs2. He and other scientists had expected the process to be more complicated.

Saitou's approach meticulously following the natural process was in stark contrast to work that others were doing, says Jacob Hanna, a stem-cell expert at the Weizmann Institute of Science in Rehovot, Israel. Many scientists try to create specific cell types in vitro by bombarding stem cells with signalling molecules and then picking through the resulting mixture of mature cells for the ones they want. But it is never clear by what process these cells are formed or how similar they are to the natural versions. Saitou's efforts to find out precisely what is needed to make germ cells, to get rid of superfluous signals and to note the exact timing of various molecules at work, impressed his colleagues. There's a really beautiful hidden message in this work that differentiation of cells [in vitro] is really not easy, says Hanna. Harry Moore, a stem-cell biologist at the University of Sheffield, UK, regards the careful recapitulation of germ-cell development as a triumph.

More here:
Stem cells: Egg engineers

Posted in Stem Cells | Comments Off on Stem cells: Egg engineers

What Rudd’s $125m could mean for regenerative medicine research

Posted: August 21, 2013 at 10:48 am

Kevin Rudd pledged $125 million for stem cell research. Regenerative medicine researcher Associate Professor Ernst Wolvetang explains the science and what the investment could mean.

What does $125 million in funding for regenerative medicine researchpledged by Prime Minister Kevin Rudd yesterdaybuy you?

Regenerative medicine is an umbrella term for therapies that involve either the delivery of stem cells to a damaged or diseased tissue or the enhancement of endogenous (stem cell mediated) repair mechanisms of the body. Its not a novel concept; a bone marrow transfer is a tried-and-tested stem cell therapy, transplanting and replacing blood cell-forming stem cells from one individual to the bone marrow of another.

Mesenchymal stem cells can be isolated from a variety of tissues such as blood, fat or placenta and have the ability to generate cartilage, fat and bone. These stem cells can home to sites of injury, have immune system-dampening properties (allowing transplantation from one donor into an unrelated person) and excrete factors that promote blood vessel formation. Because of these properties it can benefit the recovery of patients after a heart attack or other ailments. Australian company Mesoblast has been successfully developing and marketing this stem cell product.

Embryonic stem cells are probably the most powerful type of stem cell known to sciencethey can grow indefinitely andhave the ability to make anycell type of the human body. Because of their perceived ethically encumbered origin (day five surplus IVF embryos), embryonic stem cells have received a lot of attention and suffer from the drawback that delivery of embryonic stem cell-derived cells to a patient will likely involve lifelong immunosuppression (similar to organ transplants).

In recent years both the ethical barrier and the immune rejection issues have been overcome by the advent of cell reprogramming, a process pioneered by Professor John Yamanaka and Professor ShinyaGurdon, who received the Nobel Prize for their discovery. Cell reprogramming allows the artificial generation of embryonic stem cell-like stem cells (so called induced pluripotent stem cells) from small quantities of skin or blood cells. This has opened the way for the generation of patient-specific stem cells and potentially personalised stem cell repair kits.

Indeed, in animal models these induced pluripotent stem cells can, for example, generate dopaminergic cells that can improve Parkinsons disease or insulin-producing cells that can improve diabetes. Induced pluripotent stem cells now also make it possible to study genetic diseases that manifest themselves in difficult-to-access human cell types such as brain, heart and kidney cells.

The potential of such iPSC-derived cell types for drug screening has certainly not gone unnoticed by the pharmaceutical industry. The first clinical trial with iPSC-derived cells aimed at treating macular degeneration (a disease of the retina that leads to blindness) was recently started in Japan. Japan has invested more than $800 million in CIRA to accelerate iPSC cell-based therapies. Large investments in stem cell-based regenerative medicine have occurred in California ($2 billion), Canada and Europe, and China has been following suit with its own initiatives.

Dont expect miracle cures for these ailmentsbut its reasonable to expect small tangible victories in five to 10 years.

These decisions have not only been made based on the promise that stem cell-based medicine is a transformative technology for 21stcentury healthcare, but also on economic grounds given it is one of the fastest-growing industries worldwideit has an estimated current global value of $28.6 billion, expected to increase to $130.9 billion in 2018.

Read the original here:
What Rudd’s $125m could mean for regenerative medicine research

Posted in Regenerative Medicine | Comments Off on What Rudd’s $125m could mean for regenerative medicine research

Stem Cell Science ( Adult Stem Cell)-Christian Drapeau, MSc – Video

Posted: August 21, 2013 at 12:47 am


Stem Cell Science ( Adult Stem Cell)-Christian Drapeau, MSc
The gold standard in stem cell nutrition. Many people do not realize that adult stem cells play a key role in the natural renewal of your body and are essent...

By: Mario Marius

The rest is here:
Stem Cell Science ( Adult Stem Cell)-Christian Drapeau, MSc - Video

Posted in Stem Cell Videos | Comments Off on Stem Cell Science ( Adult Stem Cell)-Christian Drapeau, MSc – Video

Visualisation of Bone, Bone Marrow Cells and Stem Cells – Video

Posted: August 21, 2013 at 12:47 am


Visualisation of Bone, Bone Marrow Cells and Stem Cells

By: BoneTreatment Penang

Continued here:
Visualisation of Bone, Bone Marrow Cells and Stem Cells - Video

Posted in Stem Cell Videos | Comments Off on Visualisation of Bone, Bone Marrow Cells and Stem Cells – Video

Visualisation of Bone Marrow Cells and Stem Cells – Video

Posted: August 20, 2013 at 5:45 pm


Visualisation of Bone Marrow Cells and Stem Cells

By: BoneTreatment Penang

View post:
Visualisation of Bone Marrow Cells and Stem Cells - Video

Posted in Stem Cells | Comments Off on Visualisation of Bone Marrow Cells and Stem Cells – Video

REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 – DOH

Posted: August 20, 2013 at 5:44 pm

By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM

InterAksyon.com The online news portal of TV5

MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday.

Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits.

Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH).

Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes.

"This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added.

Among the DOH guidelines are:

Ona conceded that there are only a limited number of medical conditions in which stem cell therapy may be indicated.

Others are claims that should be taken with a grain of salt, he said.

Read more:
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 - DOH

Posted in Cell Therapy | Comments Off on REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 – DOH

Page 2,280«..1020..2,2792,2802,2812,282..2,2902,300..»